(VIANEWS) - Crexendo (CXDO), Monarch Casino & Resort (MCRI), LHC Group (LHCG) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Crexendo (CXDO)
89.7% sales growth and 15.7% return on equity
Crexendo, Inc. provides cloud communication, unified communications as a service, call center, collaboration, and other cloud business services for businesses in the United States, Canada, and internationally.
Crexendo's sales growth this year is anticipated to be 60.8% and 43.4% for next year.
Year-on-year quarterly revenue growth grew by 42.6%, now sitting on 18.75M for the twelve trailing months.
Volume
Today's last reported volume for Crexendo is 5099 which is 84.21% below its average volume of 32293.
Crexendo's sales growth is a negative 0% for the current quarter and 89.7% for the next. The company's growth estimates for the current quarter and the next is a negative 100% and negative -100%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 15.7%.
Volatility
Crexendo's last day, last week, and last month's current volatility was 0.33%, 1.54%, and 1.62%, respectively.
Crexendo's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.74% (day), 3.58% (last week), and 3.54% (last month), respectively.
Crexendo's Stock Yearly Top and Bottom Value
Crexendo's stock is valued at $6.00 at 01:22 EST, way under its 52-week high of $8.38 and way above its 52-week low of $4.90.
Crexendo's Moving Average
Crexendo's value is higher than its 50-day moving average of $5.83 and higher than its 200-day moving average of $5.94.Previous days news about Crexendo(CXDO)
- According to Bloomberg Quint on Wednesday, 29 September, "Besides Filler, other TipRanks stars include Steve Mihaylo, the CEO of telephone services company Crexendo Inc., where he owns a $60 million stake. "
2. Monarch Casino & Resort (MCRI)
60.7% sales growth and 14.11% return on equity
Monarch Casino & Resort, Inc., through its subsidiaries, owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada.
Monarch Casino & Resort's sales growth this year is anticipated to be 99.3% and 12.4% for next year.
Year-on-year quarterly revenue growth grew by 544.8%, now sitting on 290.92M for the twelve trailing months.
Volume
Today's last reported volume for Monarch Casino & Resort is 37283 which is 39.35% below its average volume of 61479.
Monarch Casino & Resort's sales growth is a negative 0% for the present quarter and 60.7% for the next. The company's growth estimates for the present quarter and the next is 73.7% and 6.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.11%.
Volatility
Monarch Casino & Resort's last day, last week, and last month's current volatility was 0.53%, 1.34%, and 2.00%, respectively.
Monarch Casino & Resort's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.48% (day), 2.37% (last week), and 3.70% (last month), respectively.
Monarch Casino & Resort's Stock Yearly Top and Bottom Value
Monarch Casino & Resort's stock is valued at $68.33 at 01:22 EST, way under its 52-week high of $76.00 and way higher than its 52-week low of $40.19.
Monarch Casino & Resort's Moving Average
Monarch Casino & Resort's value is above its 50-day moving average of $65.42 and above its 200-day moving average of $66.53.3. LHC Group (LHCG)
12.2% sales growth and 8.57% return on equity
LHC Group, Inc., a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States.
LHC Group's sales growth this year is anticipated to be 9% and 12.2% for next year.
Year-on-year quarterly revenue growth grew by 12%, now sitting on 2.13B for the twelve trailing months.
Volume
Today's last reported volume for LHC Group is 161967 which is 19.33% below its average volume of 200798.
LHC Group's sales growth for the next quarter is 12.2%. The company's growth estimates for the present quarter and the next is 3.7% and 20%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.57%.
Volatility
LHC Group's last day, last week, and last month's current volatility was 0.41%, 1.25%, and 1.51%, respectively.
LHC Group's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.71% (day), 2.52% (last week), and 2.69% (last month), respectively.
LHC Group's Stock Yearly Top and Bottom Value
LHC Group's stock is valued at $159.76 at 01:22 EST, way under its 52-week high of $236.81 and above its 52-week low of $157.27.
LHC Group's Moving Average
LHC Group's worth is under its 50-day moving average of $174.93 and way under its 200-day moving average of $194.55.4. Royalty Pharma (RPRX)
6.2% sales growth and 19.76% return on equity
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
Royalty Pharma's sales growth this year is anticipated to be 5.6% and 3.5% for next year.
Year-on-year quarterly revenue growth grew by 8.6%, now sitting on 2.24B for the twelve trailing months.
Volume
Today's last reported volume for Royalty Pharma is 1096430 which is 55.78% below its average volume of 2479860.
Royalty Pharma's sales growth for the next quarter is 6.2%. The company's growth estimates for the ongoing quarter and the next is 41.7% and 171.4%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.76%.
Volatility
Royalty Pharma's last day, last week, and last month's current volatility was 0.25%, 2.14%, and 1.32%, respectively.
Royalty Pharma's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.09% (day), 2.00% (last week), and 2.53% (last month), respectively.
Royalty Pharma's Stock Yearly Top and Bottom Value
Royalty Pharma's stock is valued at $36.23 at 01:22 EST, way under its 52-week high of $53.23 and higher than its 52-week low of $34.80.